Articles

  • 4 days ago | pharmacytimes.com | Joshua K. Sabari |Kennedy Ferruggia

    At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Joshua Sabari, MD, assistant professor of medicine and medical oncology at Perlmutter Cancer Center NYU Langone Health, presented data that examined the development of zongertinib (BI 1810631; Boehringer Ingelheim), a HER2-selective tyrosine kinase inhibitor (TKI) for the treatment of HER2-mutant advanced non-small cell lung cancer (NSCLC).

  • Nov 25, 2024 | targetedonc.com | Joshua K. Sabari

    November 25, 2024Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing the potential of various compounds for platinum-sensitive vs platinum-resistant subgroups.

  • Nov 25, 2024 | targetedonc.com | Joshua K. Sabari

    November 25, 2024Joshua K.

  • Nov 18, 2024 | targetedonc.com | Joshua K. Sabari

    November 18, 2024Joshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine residues in the minor groove of DNA, forming adducts that disrupt DNA repair mechanisms and promote apoptosis in cancer cells, noting that its action contrasts with traditional alkylating agents by specifically interfering with DNA-protein interactions and transcription processes.

  • Nov 18, 2024 | targetedonc.com | Joshua K. Sabari

    November 18, 2024Joshua K. Sabari, MD, evaluates the potential of ifinatamab deruxtecan in combination with atezolizumab, with or without platinum-based chemotherapy, as first-line induction or maintenance therapy in ES-SCLC, emphasizing that statistically significant end points such as improved PFS and OS would be essential for clinical application in this patient population.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →